Your browser is no longer supported. Please, upgrade your browser.
Settings
JAGX Jaguar Health, Inc. daily Stock Chart
JAGX [NASD]
Jaguar Health, Inc.
Index- P/E- EPS (ttm)-89.52 Insider Own12.15% Shs Outstand12.96M Perf Week-19.74%
Market Cap7.39M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float0.84M Perf Month-21.95%
Income-48.40M PEG- EPS next Q-0.51 Inst Own8.00% Short Float63.10% Perf Quarter-1.35%
Sales5.90M P/S1.25 EPS this Y71.10% Inst Trans-14.02% Short Ratio0.92 Perf Half Y-52.50%
Book/sh1.88 P/B0.30 EPS next Y88.10% ROA-126.10% Target Price4.00 Perf Year-95.29%
Cash/sh0.16 P/C3.52 EPS next 5Y40.00% ROE-899.60% 52W Range0.52 - 36.39 Perf YTD-28.84%
Dividend- P/FCF- EPS past 5Y-8.90% ROI-145.90% 52W High-98.43% Beta0.81
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin31.30% 52W Low9.15% ATR0.06
Employees17 Current Ratio0.90 Sales Q/Q-9.10% Oper. Margin- RSI (14)31.33 Volatility8.97% 7.06%
OptionableNo Debt/Eq0.61 EPS Q/Q94.40% Profit Margin- Rel Volume0.51 Prev Close0.60
ShortableNo LT Debt/Eq0.61 EarningsNov 18 Payout- Avg Volume575.80K Price0.57
Recom2.00 SMA20-18.41% SMA50-21.03% SMA200-76.90% Volume293,737 Change-4.22%
Jul-11-17Initiated Rodman & Renshaw Buy $2
Feb-20-20 08:45AM  Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award ACCESSWIRE
Feb-06-20 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. Eastern ACCESSWIRE
Jan-08-20 08:30AM  Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome ACCESSWIRE
Jan-07-20 08:50AM  One Thing To Remember About The Jaguar Health, Inc. (NASDAQ:JAGX) Share Price Simply Wall St.
Dec-16-19 08:30AM  Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients ACCESSWIRE
Dec-10-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern ACCESSWIRE
Nov-21-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern ACCESSWIRE
Nov-20-19 09:15AM  Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine ACCESSWIRE
09:00AM  MicroCap Review Magazine Fall 2019 Issue Now Available ACCESSWIRE
Nov-14-19 08:30AM  Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results ACCESSWIRE -28.80%
08:00AM  Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients ACCESSWIRE
Nov-13-19 08:30AM  Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy ACCESSWIRE
Nov-12-19 08:30AM  Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates ACCESSWIRE +25.66%
Nov-05-19 07:30AM  14 Low Float Stocks With High Short Interest Benzinga
Oct-30-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. ACCESSWIRE +20.18%
Oct-23-19 08:30AM  Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea ACCESSWIRE
Oct-22-19 08:43AM  Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI ACCESSWIRE
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals +7.97%
Oct-15-19 08:00AM  MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE
08:00AM  MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019 ACCESSWIRE
Oct-11-19 08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga -6.65%
Oct-10-19 08:30AM  Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China ACCESSWIRE
Oct-04-19 08:30AM  Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer ACCESSWIRE
Oct-01-19 08:30AM  Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE -6.87%
Sep-30-19 10:16AM  The Jaguar Health (NASDAQ:JAGX) Share Price Is Down 98% So Some Shareholders Are Very Salty Simply Wall St. +10.08%
08:30AM  Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application ACCESSWIRE
Sep-26-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern ACCESSWIRE
Sep-24-19 08:00AM  Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea ACCESSWIRE +6.43%
Sep-23-19 08:30AM  Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use ACCESSWIRE
Sep-19-19 08:30AM  Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York ACCESSWIRE
Sep-18-19 08:30AM  Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer ACCESSWIRE -8.18%
Sep-16-19 08:30AM  Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico ACCESSWIRE +7.52%
Sep-09-19 08:30AM  Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel ACCESSWIRE
Aug-26-19 08:30AM  Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs ACCESSWIRE
Aug-22-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern ACCESSWIRE -7.81%
Aug-20-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director ACCESSWIRE
Aug-19-19 04:58PM  Stock Market Today: Baidu and Sina Lead a Recovery of Chinese Stocks InvestorPlace
12:40PM  A Look At Benzinga Pro's Most-Searched Tickers For August 19, 2019 Benzinga
08:30AM  Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy ACCESSWIRE
Aug-16-19 08:30AM  Jaguar Health Appoints Carol Lizak Chief Accounting Officer ACCESSWIRE -8.26%
Aug-15-19 08:55AM  Read This Before Selling Jaguar Health, Inc. (NASDAQ:JAGX) Shares Simply Wall St. -20.39%
Aug-14-19 05:15PM  Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results ACCESSWIRE
Aug-07-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website ACCESSWIRE
Aug-02-19 08:30AM  Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea ACCESSWIRE
Jul-26-19 12:00PM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today ACCESSWIRE
Jul-23-19 04:05PM  Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option ACCESSWIRE -9.90%
Jul-18-19 08:30AM  Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering ACCESSWIRE -7.17%
Jul-15-19 08:00AM  Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE -11.88%
Jul-11-19 09:00AM  Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea ACCESSWIRE
Jun-28-19 08:00AM  Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million ACCESSWIRE
Jun-26-19 08:00AM  Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome ACCESSWIRE
Jun-25-19 07:15AM  The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership Benzinga +8.77%
Jun-24-19 08:00PM  Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards ACCESSWIRE
Jun-19-19 08:00AM  Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE -7.30%
Jun-18-19 08:00AM  Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors ACCESSWIRE
Jun-11-19 08:00AM  Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication ACCESSWIRE +35.92%
Jun-06-19 08:00AM  Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split ACCESSWIRE -20.98%
Jun-05-19 08:00AM  Jaguar Health CEO and Board Members Invest in Bridge Financing ACCESSWIRE -5.20%
Jun-03-19 08:00AM  Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 ACCESSWIRE
May-29-19 08:00AM  Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company's Balance Sheet ACCESSWIRE
May-24-19 04:15PM  Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders ACCESSWIRE
08:30AM  Jaguar Health, Inc. Reports 2019 First Quarter Financial Results ACCESSWIRE
Apr-25-19 08:00AM  Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief ACCESSWIRE
Apr-10-19 09:22AM  Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results ACCESSWIRE -7.85%
Apr-02-19 06:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi ACCESSWIRE -5.65%
Apr-01-19 08:05AM  Jaguar Health, Pipeline Review and Progress ACCESSWIRE +10.91%
Mar-28-19 06:00AM  Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi ACCESSWIRE
Mar-27-19 02:35PM  Four Biotech Stocks Setting The Standard On Wednesday ACCESSWIRE +15.38%
Mar-20-19 06:30AM  Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE -8.77%
Mar-18-19 02:00PM  Four Healthcare Stocks Heating Up On Monday ACCESSWIRE +192.64%
Mar-05-19 09:00AM  Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders ACCESSWIRE
Feb-25-19 12:00PM  Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019 ACCESSWIRE
Feb-21-19 02:09PM  What Kind Of Shareholders Own Jaguar Health, Inc. (NASDAQ:JAGX)? Simply Wall St.
Jan-24-19 09:00AM  With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product ACCESSWIRE
Jan-22-19 09:00AM  Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale ACCESSWIRE -8.15%
Jan-09-19 08:00AM  Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes ACCESSWIRE
Jan-07-19 08:00AM  Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates ACCESSWIRE +15.85%
Jan-03-19 08:00AM  Jaguar Health to Present at Biotech Showcase 2019 in San Francisco ACCESSWIRE +11.04%
Jan-02-19 08:00AM  Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance ACCESSWIRE +18.01%
Dec-06-18 08:00AM  Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer ACCESSWIRE -14.23%
Nov-14-18 08:05PM  Jaguar Health, Inc. Reports Third-Quarter 2018 Results ACCESSWIRE
Nov-13-18 08:00AM  Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th ACCESSWIRE
Oct-29-18 09:00AM  The Brilliance Behind a Global Operator of Crypto Exchanges BitMax: Understanding the Trans-Fee Mining Model ACCESSWIRE
09:00AM  Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th ACCESSWIRE
Oct-24-18 09:00AM  Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida ACCESSWIRE -9.86%
Oct-18-18 09:25AM  Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Oct-02-18 06:00AM  Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering ACCESSWIRE -24.18%
Sep-26-18 10:30AM  These Biotech and Cannabis Stocks Are Skyrocketing ACCESSWIRE -36.90%
08:00AM  Today's Research Reports on Trending Tickers: Jaguar Health and TG Therapeutics ACCESSWIRE
Sep-25-18 02:40PM  Jaguar Health's stock triples after licensing deal, has been halted 13 times for volatility MarketWatch +158.46%
Sep-24-18 04:36PM  Knight Therapeutics and Jaguar Health Announce Strategic Partnership GlobeNewswire
04:30PM  Knight Therapeutics and Jaguar Health Announce Strategic Partnership ACCESSWIRE
Aug-27-18 07:55AM  Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jul-25-18 08:00AM  RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi® GlobeNewswire
Jul-24-18 09:00AM  New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time ACCESSWIRE
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE -6.78%
Jul-16-18 09:00AM  Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference ACCESSWIRE -10.95%
Jul-12-18 09:00AM  Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates ACCESSWIRE +8.82%
Jun-28-18 09:00AM  RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi® GlobeNewswire +5.00%
09:00AM  Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product ACCESSWIRE
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Siegel Jonathan B.DirectorJul 23Buy2.0012,70525,41013,276Jul 25 04:09 PM
BOCHNOWSKI JAMES JDirectorJul 23Buy2.00180,582361,164181,618Jul 25 04:08 PM